JP2018517774A - ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法 - Google Patents

ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法 Download PDF

Info

Publication number
JP2018517774A
JP2018517774A JP2018517123A JP2018517123A JP2018517774A JP 2018517774 A JP2018517774 A JP 2018517774A JP 2018517123 A JP2018517123 A JP 2018517123A JP 2018517123 A JP2018517123 A JP 2018517123A JP 2018517774 A JP2018517774 A JP 2018517774A
Authority
JP
Japan
Prior art keywords
therapeutically effective
effective amount
nicotinamide riboside
per day
pterostilbene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018517123A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018517774A5 (https=
Inventor
マルコチュリ，エリック・アレグザンダー
グアレンテ，レナード・パーシング
アルミナナ，ダニエル・アントニオ
ボーエン，ポール・マイケル
Original Assignee
エリジウム・ヘルス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エリジウム・ヘルス・インコーポレイテッド filed Critical エリジウム・ヘルス・インコーポレイテッド
Publication of JP2018517774A publication Critical patent/JP2018517774A/ja
Publication of JP2018517774A5 publication Critical patent/JP2018517774A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2018517123A 2015-06-10 2016-02-25 ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法 Pending JP2018517774A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562173733P 2015-06-10 2015-06-10
US62/173,733 2015-06-10
PCT/US2016/019653 WO2016200447A1 (en) 2015-06-10 2016-02-25 Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders

Publications (2)

Publication Number Publication Date
JP2018517774A true JP2018517774A (ja) 2018-07-05
JP2018517774A5 JP2018517774A5 (https=) 2019-04-04

Family

ID=57503873

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018517123A Pending JP2018517774A (ja) 2015-06-10 2016-02-25 ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法

Country Status (13)

Country Link
US (2) US11426398B2 (https=)
EP (1) EP3307754B1 (https=)
JP (1) JP2018517774A (https=)
KR (1) KR20180021784A (https=)
CN (1) CN107849083A (https=)
AU (2) AU2016274126A1 (https=)
CA (1) CA2989115C (https=)
ES (1) ES2932801T3 (https=)
MX (2) MX389207B (https=)
RU (1) RU2017145692A (https=)
TW (1) TWI725033B (https=)
WO (1) WO2016200447A1 (https=)
ZA (1) ZA201800056B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018517774A (ja) 2015-06-10 2018-07-05 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
WO2018170389A1 (en) * 2017-03-17 2018-09-20 Elysium Health, Inc. Nicotinamide riboside for use in treating or preventing liver damage
US20180303861A1 (en) * 2017-04-24 2018-10-25 Eric Marcotulli Treating and preventing kidney damage
ES3004332T3 (en) * 2017-05-17 2025-03-12 Univ De Valencia Estudi General Treating and preventing amyotrophic lateral sclerosis with nicotinamide riboside and pterostilbene
US20200085849A1 (en) * 2017-05-18 2020-03-19 Elysium Health, Inc. Methods and compositions for improving sleep
CA3108015A1 (en) * 2017-07-28 2019-01-31 Centers For Age Control, Inc. Compositions and methods for preventing and reversing aspects of aging
CN109589309A (zh) * 2017-09-30 2019-04-09 浙江嘉华化工有限公司 烟酰胺核糖微囊的制备方法
JP2021500331A (ja) * 2017-10-19 2021-01-07 エリシウム ヘルス，インコーポレーテッド Ｔｄｐ−４３関連疾患の予防及び治療
WO2019108875A1 (en) * 2017-12-01 2019-06-06 Elysium Health, Inc. Methods and compositions for treating glaucoma
WO2019108873A1 (en) * 2017-12-01 2019-06-06 Elysium Health, Inc. Methods and compositions for treating multiple sclerosis
GB201811312D0 (en) * 2018-07-10 2018-08-29 Nuchido Ltd Compositions
KR102833111B1 (ko) 2018-09-25 2025-07-10 폰세 드 리온 헬스 데지그네이티드 액티비티 컴퍼니 칼슘 알파-케토글루타레이트의 제조 방법
CN111569084B (zh) * 2019-02-19 2021-07-13 中国科学院上海药物研究所 基于柳胺酚和紫檀芪的成环偶联分子dcz0801类化合物、其制备方法及用途
US12350283B2 (en) * 2019-02-26 2025-07-08 Universitat De Valencia-Estudi General Methods and compositions for treating motor neuron diseases
WO2020190703A1 (en) * 2019-03-21 2020-09-24 Elysium Health, Inc. Methods for wound treatment
CN113768946A (zh) * 2020-05-25 2021-12-10 南京帝昌医药科技有限公司 一种治疗糖尿病皮肤并发症的软膏及其制备方法
CN113712193A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 修复皮肤系统的组合物制备方法及其用途
US20230270770A1 (en) * 2020-07-30 2023-08-31 Moises HERNANDEZ-VAZQUEZ Nutritional supplements for repairing muscle and defending against deterioration from human aging
US20240335466A1 (en) * 2021-08-02 2024-10-10 Nuvamid Sa Nicotinamide mononucleotide derivatives for use in the treatment of sapho syndrome
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013509385A (ja) * 2009-10-30 2013-03-14 グリーン モールキュラー，エス．エル 皮膚の疾患、傷害または損傷の予防および／または処置における使用のためのプテロスチルベン（ｐｔｅｒ）
WO2015066382A1 (en) * 2013-10-30 2015-05-07 ChromaDex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CN101360421B (zh) 2005-11-18 2014-06-18 康乃尔研究基金会有限公司 烟酰核苷组合物及其使用方法
WO2012129499A1 (en) * 2011-03-23 2012-09-27 The Regents Of The University Of California Treatment of inflammatory and infectious skin disorders
US8841350B2 (en) * 2011-05-11 2014-09-23 ChromaDex Inc. Method for inducing UDP-glucuronosyltransferase activity using pterostilbene
US20130296440A1 (en) 2012-05-01 2013-11-07 ChromaDex Inc. Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
CA2951287A1 (en) 2014-06-06 2015-12-10 Glaxosmithkline Intellectual Property (No. 2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
CN107531738B (zh) 2015-03-16 2021-02-19 可劳迈戴斯有限公司 烟酸核苷或烟酰胺核苷组合物、其还原衍生物及其用途
US20180071273A1 (en) 2015-03-17 2018-03-15 Speccialty Nutrition Group, Inc. Nutritional compositions to enhance mitochondrial energy production
JP2018517774A (ja) 2015-06-10 2018-07-05 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013509385A (ja) * 2009-10-30 2013-03-14 グリーン モールキュラー，エス．エル 皮膚の疾患、傷害または損傷の予防および／または処置における使用のためのプテロスチルベン（ｐｔｅｒ）
WO2015066382A1 (en) * 2013-10-30 2015-05-07 ChromaDex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
JP2016538271A (ja) * 2013-10-30 2016-12-08 クロマデックス, インコーポレイテッドChromaDex, Inc. 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物

Also Published As

Publication number Publication date
CA2989115C (en) 2024-01-02
US20220362233A1 (en) 2022-11-17
MX389207B (es) 2025-03-20
AU2016274126A1 (en) 2018-01-18
EP3307754B1 (en) 2022-09-14
WO2016200447A1 (en) 2016-12-15
MX2017016024A (es) 2018-08-15
AU2020286208A1 (en) 2021-01-07
US12109206B2 (en) 2024-10-08
ZA201800056B (en) 2023-10-25
TW201713322A (zh) 2017-04-16
ES2932801T3 (es) 2023-01-26
MX2021012600A (es) 2021-11-12
EP3307754A1 (en) 2018-04-18
AU2020286208B2 (en) 2022-11-10
RU2017145692A3 (https=) 2019-07-31
RU2017145692A (ru) 2019-07-10
CA2989115A1 (en) 2016-12-15
KR20180021784A (ko) 2018-03-05
US20180353497A1 (en) 2018-12-13
EP3307754A4 (en) 2019-03-27
US11426398B2 (en) 2022-08-30
TWI725033B (zh) 2021-04-21
CN107849083A (zh) 2018-03-27

Similar Documents

Publication Publication Date Title
US12109206B2 (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
US11998561B2 (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders
US10189855B2 (en) Prodrugs of fumarates and their use in treating various diseases
AU2011376953A1 (en) Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
US12257238B2 (en) Magnesium biotinate compositions and methods of use
CN116496205B (zh) 一种卡瑞斯汀的盐及其用途
HK1254169A1 (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
HK1254169B (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
BR112017026642B1 (pt) Composições de ribosídeo de nicotinamida e pteroestilbeno e seus usos
JP6337135B2 (ja) フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
US20230321049A1 (en) Compositions of enpp1 inhibitors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200721

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201201